Guangrong Zheng

This inventor holds 23 USPTO granted patents and 13 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: University of Kentucky Research Foundation, Bioventures, LLC, University of Florida Research Foundation Inc.. Active years: 2004-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Guangrong Zheng. Retrieved from https://idiyas.com/inventor/guangrong-zheng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 23 (Patent Applications = 13)

% Patents Active = 78.3

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 2 (Patent Applications = 7)

Average Co-Inventor Count = 5.7

ph-index = 3

Forward Citations = 30(Granted Patents)

Location History:

Lexington, KY (US) (2004 - 2017)
Gainesville, FL (US) (2020 - 2022)
Little Rock, AR (US) (2016 - 2024)
Gainsville, FL (US) (2024)

Company Filing History:

12 out of 903

University of Kentucky Research Foundation

University of Florida Research Foundation Inc.

patents

4. 1 out of 961

The United States Government as Represented by the Department of Veterans Affairs

patents

5. 1 out of 851

University of Arkansas

patents

6. 2 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 2004-2026

Loading Chart...

Areas of Expertise:

Nuclear Receptor Modulators

Vesicular Monoamine Transporter-2

Cancer Treatment

BCL-2 Proteins

Senescent Cell Depletion

Nicotinic Acetylcholine Receptors

Piperlongumine Analogues

TocoFlexols

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12673106 - Modulators of nuclear receptor subfamily 4 group A member 1 (NR4A1) and uses thereof (2026-07-07),

2. 12637410 - Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse (2026-05-26),

3. 12441722 - Therapeutic agents and methods of treatment (2025-10-14),

4. 12118414 - BCL-2 proteins degraders for cancer treatment (2024-10-15),

5. 12084423 - Piperlongumine analogues and uses thereof (2024-09-10),

6. 11999676 - Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse (2024-06-04),

7. 11319316 - Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof (2022-05-03),

8. 10807977 - Compounds that induce degradation of anti-apoptotic Bcl-2 family proteins and the uses thereof (2020-10-20),

9. 10758524 - Compositions and methods for selectively depleting senescent cells (2020-09-01),

10. 10668030 - Vesicular monoamine transporter-2 ligands and their use in the treatment of psychostimulant abuse (2020-06-02),

11. 10071087 - Compositions and methods for selectively depleting senescent cells (2018-09-11),

12. 9649301 - Bis-quaternary ammonium cyclophane compounds that interact with neuronal nicotinic acetylcholine receptors (2017-05-16),

13. 9550753 - Mono quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors (2017-01-24),

14. 9540327 - Bis-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors (2017-01-10),

15. 9309547 - Methods for making tocoflexols and analogues thereof (2016-04-12),

Title: Innovations in Cancer Treatment: The Contributions of Guangrong Zheng

Introduction: Guangrong Zheng, based in Lexington, KY, has emerged as a significant figure in the field of biomedical research, holding a remarkable portfolio of 20 patents. His innovative work focuses primarily on the development of novel therapeutic strategies for cancer treatment and age-related disorders.

Latest Patents: Zheng’s most recent patents showcase his commitment to advancing medical science. One notable invention involves BCL-2 proteins degraders specifically designed for cancer treatment. This groundbreaking composition offers a method for selectively killing cancer cells with improved potency and safety, showcasing reduced platelet toxicity while maintaining or enhancing toxicity toward cancer cells. Another patent highlights his exploration of piperlongumine analogues and their applications in selectively eliminating senescent cells, potentially delaying aging and addressing age-related health issues.

Career Highlights: Throughout his career, Guangrong Zheng has made substantial contributions to the field while working with esteemed organizations. Notable affiliations include the University of Kentucky Research Foundation and Bioventures, LLC, where he has actively engaged in pioneering research that bridges the gap between laboratory innovation and clinical application.

Collaborations: Zheng has had the privilege of collaborating with esteemed colleagues, including Peter Anthony Crooks and Linda P Dwoskin. Such partnerships have significantly enhanced the breadth and impact of his research, driving forward the mission to create effective therapeutic solutions.

Conclusion: Guangrong Zheng’s impressive array of patents and collaborations underscores his impact on innovations in cancer treatment and aging research. His dedicated work is not only contributing to advancements in medical science but also improving the quality of life for countless individuals facing these significant health challenges.

Profile summary based on public USPTO records.